While Rhythm Pharmaceuticals Inc has overperformed by 3.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RYTM rose by 77.58%, with highs and lows ranging from $116.00 to $45.90, whereas the simple moving average jumped by 28.82% in the last 200 days.
On November 05, 2025, Oppenheimer Downgraded Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) to Perform. A report published by Goldman on July 10, 2025, Initiated its previous ‘Buy’ rating for RYTM. Leerink Partners also rated RYTM shares as ‘Outperform’, setting a target price of $88 on the company’s shares in an initiating report dated July 07, 2025. Stifel initiated its ‘Buy’ rating for RYTM, as published in its report on March 05, 2025. Jefferies’s report from January 02, 2025 suggests a price prediction of $80 for RYTM shares, giving the stock a ‘Buy’ rating. Oppenheimer also rated the stock as ‘Outperform’.
Analysis of Rhythm Pharmaceuticals Inc (RYTM)
Further, the quarter-over-quarter increase in sales is 54.28%, showing a positive trend in the upcoming months.
One of the most important indicators of Rhythm Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -240.36% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.53, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and RYTM is recording 618.26K average volume. On a monthly basis, the volatility of the stock is set at 4.81%, whereas on a weekly basis, it is put at 4.58%, with a loss of -0.89% over the past seven days. Furthermore, long-term investors anticipate a median target price of $126.31, showing growth from the present price of $99.41, which can serve as yet another indication of whether RYTM is worth investing in or should be passed over.
How Do You Analyze Rhythm Pharmaceuticals Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 7.09%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 105.75% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
